Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 1

NCT06176690

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

This study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to…

United States90 participantsStarted 2025-10-27

Treatment: C7R.CD30.CAR-EBVST cells

All recent trials (17 shown)

Active — Not RecruitingPhase 1/2

NCT06035497

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With R…

The purpose of this study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 (Golcadomide) in participants with relapsed or refractory…

Japan85 participantsStarted 2023-11-20

Treatment: BMS-986369

Active — Not RecruitingPhase 2

NCT03703050

Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Dis…

Prospective, non-randomized, single arm phase II trial with 2 cohorts of ALK+ ALCL treated with nivolumab

Denmark, France45 participantsStarted 2019-01-02

Treatment: Nivolumab cohort 1, Nivolumab cohort 2

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

All recent trials (17 shown)

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With R…

Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Dis…

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

All recent trials (17 shown)

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With R…

Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Dis…

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-H…

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL

Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study

Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL

UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas